Burroughs Wellcome Co.

Medeva Pharma Limited

Ucb Pharma Gmbh

Evans Medical Limited

Pavel Novotny

Juraj Ivanyi

Juan Antonio Crespo

Juan Antonio Montaraz Crespo

Jaroslava Novotny

An acellular vaccine is provided which in use provides protection againstinfections. The vaccine is based on the synergistic combination of two antigenes from, the 69 kDa, and the filamentous haemagglutinin antigens.

[object Object]

The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of,, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.

Antigenic preparations and isolation of such preparations

The invention provides a vaccine containing a proteinaceous material derived from the outer membrane of Bordetella pertussis, wherein the proteinaceous material is characterized by a relative molecular weight of about 67,000 to 73,000, preferably 69,000, as determined by 12% (w/w) polyacrylamide gel electrophoresis and a proline:glutamic acid ratio of about 1:1 as determined by amino acid analysis, in a pharmaceutically acceptable carrier or adjuvant. The invention also provides a method of inducing an immune response in an individual involving administering the vaccine of the invention to an individual.

Antigenic preparations and the isolation of such preparations

The invention provides a vaccine containing a proteinaceous material derived from the outer membrane of Bordetella pertussis, wherein the proteinaceous material is characterized by a relative molecular weight of 67,000 to about 73,000, preferably 69,000, as determined by 12% (w/w) polyacrylamide gel electrophoresis, and has a proline:glutamic acid ratio of about 1:1, in a pharmaceutically acceptable carrier or adjuvant. The invention also provides a method of inducing an immune response in an individual involving administering the vaccine of the invention to an individual.

Purified Bordetella pertussis antigen having a molecular weight between 67,000 and 69,000 and determined by 12% (W/W) polyacrylamide gel electrophoresis and a proline glutamic acid ratio of substantially 1:1 as determined by amino acid analysis.

Antigenic preparation and isolation of such preparations

The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B. pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.

Growing community of inventors

Beckenham, United Kingdom

Pavel Novotny